

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: **MORSEY, ET AL.** :
APPLICATION NO.: **NOT YET ASSIGNED** : Examiner: **NOT YET ASSIGNED**
FILING DATE: **HEREWITH** : Group Art Unit: **NOT YET ASSIGNED**
TITLE: **ANTI-IgE VACCINES** :

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

In the Specification

Please add the following paragraph beginning at page 1, line 1 of the specification:

--- Cross Reference to Related Applications

This application claims the benefit of priority from United States Provisional
Application No. 60/228,989, filed August 30, 2000.---

EXPRESS MAIL NO. EL639818052US


REMARKS

Enclosed herewith, is a marked up version of the changes made to the specification,
entitled "**Versions with markings to show changes made**".

Applicant respectfully requests a timely Notice of Allowance be issued in this case.

Respectfully submitted,

Date: August 24, 2001


Lorraine B. Ling
(Attorney for Applicant(s))
Reg. No. 35,251

Pfizer Inc
235 East 42nd Street
New York, NY 10017-5755
(212) 573-2030

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

New paragraph beginning at line 1, page 1 has been added as follows:

Cross-Reference to Related Applications

This application claims the benefit of priority from United States Provisional Application No. 60/228,989, filed August 30, 2000.

[illegible]